



Molecular Dynamics, Docking and Prediction of Absorption, Distribution, Metabolism and Excretion of Lycopene as Protein Inhibitor of Bcl2 and DNMT1

Farida Rahim¹, Purnawan P Putra², Friardi Ismed², Andani E Putra³, Henny Lucida²¹Faculty of Pharmacy, Universitas Perintis Indonesia, Padang, Indonesia;²Faculty of Pharmacy, Universitas Andalas, Padang, Indonesia;³Faculty of Medicine, Universitas Andalas, Padang, Indonesia.

ARTICLE INFO

Article history:

Received 02 June 2023

Revised 19 June 2023

Accepted 10 July 2023

Published online 01 August 2023

ABSTRACT

Docking has been used currently in the early development of a drug candidate and a useful tool to predict the absorption, distribution, metabolism, and excretion (ADME) properties. Lycopene shows the strongest antioxidant activity among carotenoids, and has anticancer activity. This study predicts the ADME and simulates the docking of lycopene to predict the binding to the B-cell lymphoma 2 (Bcl2) and DNA (cytosine-5)-methyltransferase 1 (DNMT1) proteins in cancer cells. The computational method was conducted using pkCSM and SWISS ADME applications, and Glna software to simulate lycopene docking to the proteins. Results show that lycopene has a molecular weight > 500, partition coefficient (log P) > 5, with a limited aqueous solubility, low skin permeability, however shows a good intestinal permeability and an active uptake through the blood brain barrier, the Convolutional Neural Network (CNN) Pose Score in protein Bcl2 of 0.7843, and DNMT1 score of 0.1279. Lycopene is predicted to have an interaction with Bcl2. There is a pi-alkyl interaction with amino acids PHE63 and TYR67, and a Pi-Sigma interaction with amino acid TYR161. ARG66, ALA108, LEU96, MET74, and VAL92 are among the amino acids that exhibit alkyl-alkyl interactions. Homology modelling was implemented due to the presence of a gap in the sequence within the chain, specifically between residues 31 and 49. The stability of lycopene-substrate interactions was evident during 20 ns molecular dynamics simulations, indicating its consistent behavior over the duration.

Copyright: © 2023 Rahim *et al.* This is an open-access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Keywords: Lycopene, Cancer, Docking, Molecular Dynamics, Bcl2, DNMT1

Introduction

Lycopene is a secondary metabolite of the carotenoid group, which shows the strongest antioxidant activity when compared to other carotenoids such as α -carotene, β -carotene, zeaxanthin and lutein.¹ The bioactivity of lycopene as an anticancer agent has been tested in vitro, in vivo, and in epidemiological studies. In addition to its radical scavenging activity, the molecular mechanism of lycopene have been reported such as the inhibition of cell proliferation, the inhibition of cell cycle progression via modulating cell cycle regulatory proteins, the induction of apoptosis, and the regulation of several signal transduction pathways.¹ Previous studies have tested lycopene extract from tomato products against apoptosis, tumor protein 53 (TP53), Bcl-2 Associated X-protein (BAX), and Bcl2 expression in prostate cancer. The results showed that lycopene from four of tomato products inhibited cell viability, increased apoptosis and regulated transcriptional expression levels of TP53, BAX and Bcl2 prostate cancer cells at the dose used.² Studies on the effect of lycopene on cell viability in several human cancer cell lines using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay have also been carried out, showing that the anticancer potential of lycopene on cell viability depends on time of exposure and dose.³

Bcl2 and DNMT1 are proteins involved in cancer, Bcl2 has an important role in regulating apoptosis, the process of apoptosis through the mitochondrial pathway occurs due to caspase activation (caspase cascade). This activation is regulated by the Bcl2 group protein which plays a role in influencing mitochondrial permeability for the release of cytochrome C into the cytosol and binds to Apoptotic Protease Activating Factor-1 (APAF1) to form the apoptosome. This apoptosome activate pro-caspase-9 to caspase-9 which will inhibit cell death. DNMT1 is a protein that catalyzes DNA methylation which responsible for causing cervical cancer. It inhibits the transcription of tumor suppressor genes and facilitates tumorigenesis formation and finally develops into cervical cancer cells. From this explanation, these two proteins were selected for lycopene docking simulations to obtain the information about an interaction of lycopene with Bcl2 and DNMT1 as the basis for the in vitro test of lycopene as an anti-cancer drug, especially cervical cancer.^{2,3}

The use of computing in the field of chemical research is a new trend in the development of new drugs, such as using Artificial Intelligence (AI), databases and big data, thereby helping to understand the properties of a compound much more quickly and effectively in screening new drug candidates.^{4,5} Modelling the interaction between substances and biological targets provides an initial description of the physicochemical properties, toxicological effects and potential drug targets using computational methods (Machine Learning).⁶ This study was conducted to predict the absorption, distribution, metabolism, excretion and to simulate docking of lycopene with proteins to predict its binding to Bcl2 and DNMT1 proteins.

Materials and Methods

Docking Simulation

The simulation in this study was conducted using a Graphics Processing Unit (GPU) 1660 Super with CUDA version 11.6. The target protein

*Corresponding author. E mail: hennylucida@phar.unand.ac.id;hennylucida@gmail.com

Tel: +62 81363403686; +62 751 71682

Citation: Rahim F, Putra PP, Ismed F, Putra AE, Lucida H. Molecular Dynamics, Docking and Prediction of Absorption, Distribution, Metabolism and Excretion of Lycopene as Protein Inhibitor of Bcl2 and DNMT1. 2023; 7(7):3439-3444 <http://www.doi.org/10.26538/tjnpr/v7i7.23>

Official Journal of Natural Product Research Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria.

Bcl2 (PDB 4EIH⁷ and DNMT1 Chain B (PDB 4WXX) used in this study were downloaded on the website of protein data bank <https://www.rcsb.org/>.⁸ Simulation of Docking was conducted using Software Glna version 1.0.2 with blind docking.⁹ This software is used as Deep Learning scoring function. The natural ligands from protein crystallography were compared with the docking results. This was done to see the Root Mean Square Deviation (RMSD) value. The RMSD score < 2 is the validation parameter employed, and it shows how closely the software can simulate molecular docking to crystallographic results. A rectangular prism will be automatically generated to find the maximum coordinates of x, y, and z using the CNN verbose software in Glna. The simulation will use a grid box with exhaustiveness set at 64 and an autobox ligand. Tight bindings from xTB version 6.0.4 are used to perform geometry optimization on lycopene molecules.¹⁰ Predictive analysis of docking interactions between protein and lycopene was analyzed using Discovery Studio version 2022.

Absorption, Distribution, Metabolism, and Excretion (ADME) predictions

The PKSCM website (<http://structure.bioc.cam.ac.uk/pkscm>) was used to analyze lycopene's ADME.⁶

Homology Modeling

Homology modelling was built using the Bcl2 protein to solve the missing residue. It used SWISS-MODEL <https://swissmodel.expasy.org/>.^{10, 11, 12} The search for templates was done first and followed by building the new model. The homology modelling pdb file is superposed using Chimera.

Molecular Dynamics

Gromacs version 2022.2 was used to simulate molecular dynamics.¹³ The proteins preparation was carried out using pdb2gmx, employing AMBER14SB force field.¹⁴ Parameter and topology file were prepared using ACPYPE with GAFF2 force field.^{15, 16} The water model used was TIP3P.¹⁷ A minimization process was carried out using 50,000 steps, with a maximum force threshold at < 1000.0 kJ/mol/nm. The equilibration stage used a canonical ensemble (NVT) with a verlet cutoff scheme and a coulomb type Particle Mesh Ewald (PME) with a step of 100 ps.¹⁸ Then proceed with the isothermal-isobaric equilibration (NPT) process with Parinello-Rahman pressure coupling.¹⁹ The production of simulation was carried out for 20 ns at a temperature of 310 K.²⁰

Result and Discussion

Lipinski have analyzed more than 2000 drug compounds in clinical trials and concluded that a drug compound will have good absorption or permeation if the molecular weight is less than 500 Da, the log P value is less than 5, the number of hydrogen bond donors is less than 5, and the number of hydrogen bond acceptors is less than 10.²¹ The Lipinski's rule analyzed the physicochemical properties of ligands to determine the hydrophobic-hydrophilic character of a compound and the passage through cell membranes by passive diffusion.²¹ This rule was later called the "Lipinski Rule of Five".²² The molecular weight of lycopene (Table 1) is more than 500 Da, thus it cannot diffuse across the cell membrane. Log P values greater than 5 indicates that the compound tends to have a very large volume of distribution leaving low concentration in blood therefore the selectivity of binding to the target enzyme is reduced. If Log P value is too low the molecule cannot pass through the lipid bilayer membrane due to its hydrophilic properties.²¹ The number of hydrogen bond donors and acceptors describes the capacity for absorption, the higher the hydrogen bonding capacity, the higher the energy required for the absorption process to occur. Lycopene has neither a proton donor or acceptor in its chemical structure, indicating that it requires high energy to be absorbed, primarily via carrier mediated transport.²³ In general, Lipinski's rule describes a prediction of the ability of compounds to penetrate cell membranes by passive diffusion.²²

Data in Table 2 suggest the ADME prediction of lycopene based on its physicochemical parameters obtained from the docking simulation. The solubility data confirms that lycopene has limited solubility in water,

however it shows good intestinal permeability (log Paap > -5 cm/s).^{21, 24} The skin permeation coefficient (log Kp) value of -2.738 shows that lycopene has low skin permeability. The permeability surface area products (log PS) and the blood brain barrier permeability (log BB) values are high (> -4.5) indicating that lycopene is permeable to the brain through active uptake processes.^{25, 26} Lycopene does not metabolized by CYP1A2, CYP2C19, and CYP3A4 enzymes in the liver, however the data show overall clearance value of 1.949 ml/min/kg which means that it is anticipated to be eliminated quickly through metabolism of other enzymes or other route of excretion.

The role of Bcl2 in the process of apoptosis is through the intrinsic pathway by influencing mitochondrial permeability to release cytochrome C into the cytosol, which then binds to Apoptotic Protease Activating Factor-1 (APAF1) to form apoptosomes. The apoptosome will activate pro-caspase-9 to become caspase-9 which is the executioner of cell death. DNMT1 is essential in maintaining and regulating DNA methylation. Abnormal expression of DNMT1 leads to aberrant methylation of several CpG tumour suppressor genes, resulting in an inactivation of tumour suppressor genes and cell carcinogenesis. The interaction mechanism can be predicted with an in silico approach, especially with molecular docking.²⁷

The target protein for Bcl2 and DNMT1 is accessible for downloading in the form of PDB. Bcl2 and DNMT1 were obtained from separating the proteins from water molecules and their ligand compounds. The protein's crystal structure is then saved in the PDB file. The validation stage by Glna (Figure 1) involves re-docking the produced ligands with Bcl2 and DNMT1. Preparation of Gridbox uses an autobox from Glna that will automatically provide Grid information in a form that corresponds to the natural ligand of the receptor.

Table 1: The physicochemical properties of lycopene

No	Physicochemical Properties	Value for lycopene	Lipinsky Rule
1.	Molecular weight	536.888	< 500 Da
2.	Log P	12.938	< 5
3.	Rotatable bond	16	na
4.	Proton acceptor	0	< 10
5.	Proton donor	0	< 5
6.	Surface area	248.007	na

*na = data are not available

Table 2: Prediction of the ADME of Lycopene

No	ADME	Value
1.	Absorption	
	Water solubility	-6.514 (log.mol/L)
	P-glycoprotein substrat	Yes
	Intestinal absorption	93.238 (Log Papp in 10 ⁻⁶ cm/s)
	Skin-Permeability	-2.738 (%)
2	Distribution	
	BBB Permeability	1.086 (Log BB)
	CNS Permeability	-0.267 (Log PS)
3	Metabolism	
	CYP1-A2	No
	CYP2C19	No
	CYP3A4	No
4	Excretion	
	Total Clearance	1.949 (Log ml/min/Kg)

tested complexes was achieved after the simulation ran for more than 20 ns with fluctuations of Lycopene ranging from 0,1-0,29 nm. As for the native ligand, the movement of the RMSD ranges from 0.1-0.3 nm. The results of the RMSD plot analysis above can be compared with the docking data, which describes the complex state between protein and Lycopene molecules during the time simulation process.^{29,30}

Root Mean Square Fluctuation (RMSF) analysis was carried out in this study (Figure 9). The purpose of the RMSF analysis is to observe the flexibility during the simulation time. Results showed that RMSF between Native Ligand and Lycopene had relatively the same fluctuations in amino acid residues. The most fluctuating residue is the amino acid Histidine 53.

Conclusion

The physicochemical properties of lycopene do not comply with Lipinsky rules for drug candidates, but ADME predictions show that lycopene has good intestinal permeability and is permeable through the blood-brain barrier. The CNN Pose Score in Bcl2 protein is 0.7843, and the DNMT1 score is 0.1279. The binding of lycopene with Bcl2 is spontaneous and is stronger than the binding with DNMT1. Molecular Dynamics Simulation shows that lycopene is stable in the remaining 20 ns in the protein complex.

Conflict of Interest

The authors declare no conflict of interest.

Authors' Declaration

The authors hereby declare that the work presented in this article is original and that any liability for claims relating to the content of this article will be borne by them.

Acknowledgements

Ms Farida Rahim acknowledged the financial support of Universitas Perintis which enabled her to pursue this study.




Figure 4: Visualization of Bcl2 protein (A) and Homology modeling protein (B)



Figure 5: Superposed protein Bcl2 and the results of homology modelling (dotted lines indicate the presence of a sequence gap)




Figure 6: Local Quality Estimate




Figure 7: Local Quality Estimate and Comparison with non-redundant set of PDB structures




Figure 8: The RMSD protein results between native ligand and lycopene




Figure 9: RMSF results between Bcl2 Protein with Native Ligand (Red) and Lycopene (Magenta)

References

1. Qi WJ, Sheng WS, Peng C, Xiaodong M, Yao TZ. Investigating into anti-cancer potential of lycopene: Molecular targets. *Biomed Pharmacother.* 2021; 138: 111546. Doi: 10.1016/j.biopha.2021.111546.
2. Soares N, Machado CL, Trindade BB, Lima IC, Gimba ERP, Teodoro AJ, Takiya C, Borojevic R.. Lycopene extracts from different tomato-based food products induce apoptosis in cultured human primary prostate cancer cells and regulate TP53, Bax and Bcl2 transcript expression. *Asian Pac J. Cancer Prev.* 2017; 18(2): 339–345. Doi: [10.22034/APJCP.2017.18.2.339](https://doi.org/10.22034/APJCP.2017.18.2.339).
3. Teodoro AJ, Oliveira FL, Martins NB, Maia GA, Martucci RB, Borojevic R.. Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines. *Cancer Cell Int.* 2012; 12 (1): 36. Doi: [10.1186/1475-2867-12-36](https://doi.org/10.1186/1475-2867-12-36).
4. Quy PT, Bui TQ, Bon NV, Phung PTK, Duc DPN, Nhan DT, Phu NV, To DC, Nhung NTA. Euonymus laxiflorus Champ. Bioactive Compounds Inhibited α -Glucosidase and Protein Phosphatase 1B – A Computational Approach Towards the Discovery of Antidiabetic Drugs. *Trop J. Nat Prod Res.* 2023; 7(5):2974-2991. Doi: 10.26538/tjnpr/v7i5.21.
5. Fadana Y, Dinana IA, Srihardyastutie A, Rollando R, Masruri M. Screening Indonesian Pine (Pinus merkusii Jungh at de Vriese) Compound as an Antibacterial Agent: In Vitro and In Silico Study. *Trop J. Nat Prod Res.* 2023; 7(3): 2586-2595. Doi: 10.26538/tjnpr/v7i3.19.
6. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. *J. Med Chem.* 2015; 58(9): 4066–4072. Doi: [10.1021/acs.jmedchem.5b00104](https://doi.org/10.1021/acs.jmedchem.5b00104).
7. Touré BB, Miller-Moslin K, Yusuff N, Perez L, Doré M, Joud C, Michael W, Dipietro L, Van Der Plas S, McEwan M, Lenoir F, Hoe M, Karki R, Springer C, Sullivan J, Levine K, Fiorilla C, Xie X, Kulathila R, Visser M. The Role of the acidity of N-heteroaryl sulfonamides as inhibitors of Bcl2 family protein-protein interactions. *ACS Med Chem Lett.* 2013; 4(2): 186–190.
8. Zhang ZM, Liu S, Lin K, Luo Y, Perry JJ, Wang Y, Song J. Crystal Structure of Human DNA Methyltransferase 1. *J. Mol Biol.* 2015; 427(15):2520–2531. Doi: 10.1016/j.jmb.2015.06.001.
9. McNutt AT, Francoeur P, Aggarwal R, Masuda T, Meli R, Ragoza M, Sunseri J, Koes DR. Gnina 1.0: molecular docking with deep learning. *J. Cheminformatics.* 2021; 13: 43.
10. Bannwarth C, Ehlert S, Grimme S. GFN2-xTB - An Accurate and Broadly Parametrized Self-Consistent Tight-Binding Quantum Chemical Method with Multipole Electrostatics and Density-Dependent Dispersion Contributions. *J. Chem Theory and Comput.* 2019; 15(3): 1652–1671. Doi: 10.1021/acs.jctc.8b01176.
11. Suharti N, Dachriyanus, Lucida H, Wahyuni FS, Hefni D, Putra PP. In Silico Prediction and *In Vitro* Cytotoxic Activity of Arbuscular Mycorrhizal Fungi Induced Zingiber officinale Var. Rubrum. *Res. J. Pharm Technol.* 2022; 15(11): 4913-8. Doi: [10.52711/0974-360X.2022.00825](https://doi.org/10.52711/0974-360X.2022.00825).
12. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, De Beer TAP, Rempfer C, Bordoli L, Lepore R, Schwede T. SWISS-MODEL: Homology modelling of protein structures and complexes. *Nucleic*

- Acids Res. 2018; 46 (W1), W296–W303. Doi: 10.1093/nar/gky427.
13. Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, Lindahl E. Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX*. 2015; 1–2: 19–25. Doi: 10.1016/j.softx.2015.06.001.
 14. Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. *J. Chem Theory Comput*. 2015; 11(8): 3696–3713. Doi.org/10.1021/acs.jctc.5b00255.
 15. Sousa Da Silva AW, Vranken WF. ACPYPE - AnteChamber PYthon Parser interfacE. *BMC Res Notes*. 2012; 5: 367. Doi.org/10.1186/1756-0500-5-367.
 16. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general Amber force field. *J. Comput Chem*. 2004; 25(9): 1157–1174. Doi: 10.1002/jcc.20035.
 17. Mark P, Nilsson L. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. *J. Phys Chem A*. 2001; 105(43): 9954–9960. Doi: 10.1021/jp003020w.
 18. Darden T, York D, Pedersen L. Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems. *J. Chem Phys*. 1993; 98(12): 10089–10092. Doi: 10.1063/1.464397.
 19. Parrinello M, Rahman A. Polymorphic transitions in single crystals: A new molecular dynamics method. *J. Appl Phys*. 1981; 52(12): 7182–7190. Doi: 10.1063/1.328693.
 20. Putra PP, Junaidin. Molecular dynamics simulation of protein-ligand, calculation of MMPBSA and MMGBSA using GROMACS. (1st ed.). 2022. Future Science.
 21. Lipinsky CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev*. 1997; 23: 3-25.
 22. Lipinski CA. Lead- and drug-like compounds: The rule-of-five revolution. *Drug Discov Today Technol*. 2004; 1(4): 337–341. Doi: 10.1016/j.ddtec.2004.11.007.
 23. Puah BP, Jalil J, Attiq A, Kamisah Y. New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene. *Molecules*. 2021; 26: 3888. Doi: 10.3390/molecules26133888.
 24. Dahlgren D, Lennernas H. Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and *In Vivo* Approaches. *Pharmaceutics*. 2019; 11: 411. Doi: 10.3390/pharmaceutics11080411.
 25. Goenawan H, Pratiwi YS, Dewi NP, Achadiyani A, Sylviana N. Beneficial Effect of Lycopene on Diabetes Mellitus and its Possible Mechanism: A Review. *Trop J. Nat Prod Res*. 2021; 5(3): 420-433. Doi: 10.26538/tjnpr/v5i3.2.
 26. Geldenhuys WJ, Mohammad AS, Adkins CE, Lockman PR. Molecular determinants of blood–brain barrier permeation. *Ther Deliv*. 2015; 6(7): 961–971.
 27. Sowndhariya S, Ravi S, Dharani J, Sripathi R. Chemical Constitution, In-silico Molecular Docking Studies and Antibacterial Activity of Flower Essential Oil of *Artabotrys hexapetalus*. *Jordan J. Pharm Sci*. 2022; 15(3): 341–354. Doi: 10.35516/jjps.v15i3.408.
 28. Aktepe OH, Şahin TK, Güner G, Arik Z, Yalçın Ş. Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor-kappa b (NF- κ b) pathway. *Turkish J. Med Sci*. 2021; 51(1):368–74.
 29. Arpudhamary V, Priya S, Manzoor MAP, Mubarakali D, Hemalatha S. Apoptotic-inducing factor 1 (AIF1) plays a critical role in cembranoid mediated apoptosis to control cancer: Molecular docking and dynamics study. *Biocatal Agric Biotechnol*. 2019; 22.
 - Putra PP, Fauzana A, Salva KA, Sofiana M, Sari IP, Lucida H. Homology modeling and mutation prediction of ACE2 from COVID-19. *Pharmaciana*. 2021; 11(2): 163. Doi: 10.12928/pharmaciana.v11i2.19089..